Venatorx Pharmaceuticals was founded in June 2010 by our three visionary, fearless leaders Drs. Christopher J. Burns, Daniel C. Pevear and Luigi Xerri. We have established a world-class in-house research and development organization that has file over 120 patents and advanced multiple in house discovery programs to clinical stage. Cheers to the many milestones to come as we work purposefully every day to get antibiotics and antiviral therapies into the hands of physicians to effectively treat patients. Below are just a few of the highlights!
Filed NDA for Cefepime-Taniborbactam
Awarded BARDA Contract for Ceftibuten-Ledaborbactam Etzadroxil program
Entered Commercial Partnerships with Melinta and Menarini
Awarded BARDA Project BioShield Contract
Raised Series C Financing
Announced Positive Results for Phase 3 CERTAIN-1 cUTI Study for
Cefepime-Taniborbactam
Expanded Anti-Infectives Portfolio with HBV Candidate Hepatitis B Virus
Named ‘Best Places to Work’ Fourth Year in a Row
Awarded NIH/NIAID Contract
Named ‘Best Places to Work’ Third Year in a Row
Partnered with GARDP
Initiated Phase 3 Trial for Cefepime-Taniborbactam
Named ‘Best Places to Work’ Second Year in a Row
Announced Collaboration with BARDA (ASPR) and DTRA
Founders Named EY ‘Entrepreneurs of the Year’
President and CEO Named LSPA ‘CEO of the Year’
Entered Exclusive License Agreement with Everest Medicines II Limited
Named Best Places to Work
Received Award from DTRA
Received FDA’s QIDP/Fast Track Designation for Taniborbactam (VNRX-5133)
Received Funding from CARB-X
Raised $42M Series B Financing
Awarded NIH R01 Grant
Completed $3.5M Series A Financing
Awarded Funding from The Wellcome Trust
Awarded NIH Contract
Awarded Phase 1 SBIR Grant
Awarded NIH R01 Grant
Founded by Drs. Burns, Pevear and Xerri
You are using a browser that is not supported. Please consider changing your browser |